hrp0092p2-246 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology | ESPE2019

Comparison of Growth Status, Level of Blood Glucose and Lipid Metabolism in SGA and AGA Girls with Central Precocious Puberty

Yang Xi , Yu Xiao , Zhao Yue , Luo Xiaoping , Liang Yan , Wu Wei , Ying Yanqin , Hou Ling

Background: Several studies have shown that born small for gestational age (SGA) children have earlier precocious puberty, progress faster, and are less likely to gain target height in adults than children born appropriate for gestational age (AGA). Moreover, SGA children are more prone to metabolic disorders - obesity, diabetes and cardiovascular disease.Objective: To compare the physical development status, serum lipid...

hrp0086p1-p248 | Diabetes P1 | ESPE2016

GCK Mutations in Chinese MODY2 Patients: A Family Pedigree Report and Review of Chinese Literature

Ping Xiao Yu , Xu Xiao Hua , Lan Fang Yan , Qiong Jiang Li , Chen Chun , Liang Li , Lin Wang Chun

Background: Maturity-onset diabetes of the young, type 2 (MODY2), caused by mutations in the glucokinase (GCK) gene is rare in a Chinese population.Objective and hypotheses: We report three Chinese families with MODY2 and sequenced the GCK gene to find novo mutation.Method: Three unrelated Chinese families with MODY2 and pedigrees were investigated. In Family 1, the proband was a 7-year-old girl with impaired fasting glucose (IFG) ...

hrp0098p1-80 | Pituitary, Neuroendocrinology and Puberty 1 | ESPE2024

A 12-month, Open-Label, Single-Arm, Phase 3 Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty

Yu Xiao , Cheng Xinran , Xu Xu , Gong Chunxiu , Li Guimei , Yao Hui , Zhou Li , Zhong Yan , Yang Yu , Luo Feihong , Zhang Yining , Huang Frank , Shi Xiaofeng , Cabri Patrick , Luo Xiaoping

Objectives: The gonadotropin-releasing hormone (GnRH) analogue triptorelin is used to treat central precocious puberty (CPP) in 1-, 3- and 6-month prolonged-release (PR) formulations. Currently, only the 1- and 3-month formulations are approved for CPP in China. However, the 6-month formulation is available for CPP treatment in numerous countries; this study assessed the efficacy and safety of this formulation in Chinese children with CPP.<p class="abstext...